The Single Cell and Spatial Omics Conference comes at a pivotal moment, as transformative multi-modal technologies are rapidly redefining our understanding of disease biology and therapeutic discovery. Despite remarkable advances, a significant translational gap remains between state-of-the-art omics tools and their integration into clinical practice—particularly for diseases contributing disproportionately to global disability-adjusted life years (DALYs).

This meeting brings together an unparalleled cross-section of academic innovators and industry leaders who are advancing the frontiers of single-cell genomics, spatial biology, and perturbation technologies. By intentionally bridging these modalities and focusing on high-burden disease areas, the conference aims to accelerate the development of clinically actionable insights. Attendees will hear from key figures driving the next generation of atlas technologies and computational frameworks, and explore how large-scale reference maps can inform therapeutic hypotheses and biomarker strategies.

The program is designed to foster interdisciplinary collaboration, convening computational biologists, technologists, immunologists, and clinician-scientists who rarely share the same stage. Speakers from leading institutions—including the Icahn School of Medicine, Yale, Weizmann Institute, A*STAR, Austrian Academy of Sciences, Memorial Sloan Kettering, VIB, and the Broad Institute—will engage with representatives from pioneering companies such as Atlasomics, Bruker, Cellanome, and Novo Nordisk.

In addition to the scientific agenda, the meeting includes targeted programming for early-career scientists to explore diverse professional pathways at the interface of academia, biotech, and industry. This unique convergence positions the conference as the premier venue for translating cutting-edge single-cell and spatial technologies into meaningful clinical applications, and for shaping the future of translational omics.